An Alpharetta biotech company plans to raise $25 million for a variety of cardiovascular applications, including a treatment to repair damaged heart muscle due to congestive heart failure.
Privately held CorMatrix Cardiovascular Inc. CorMatrix Cardiovascular Inc. Latest from The Business Journals Bush, Tenet directors’ cash pay jumpsJeb Bush, Tenet directors’ 2008 pay upJeb Bush, Tenet directors’ 2008 pay up Follow this company is developing biomaterial devices that harness the body’s innate ability to repair damaged heart tissue.
CorMatrix has developed a device that acts like a scaffold into which the patient’s stem cells migrate and integrate, stimulating the body’s wound-healing mechanisms to repair tissue at the site of implantation. As the patient’s cells populate the matrix, they lay down their own collagen, which matures over time to repair the...
